APA (7th ed.) Citation

JJ, M., JF, M., AC, M., SA, D., PC, T., BV, P., . . . J, H. (2022). Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Immunology letters, 251-252, 20. https://doi.org/10.1016/j.imlet.2022.10.002

Chicago Style (17th ed.) Citation

JJ, Morales-Núñez, Muñoz-Valle JF, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Panduro-Espinoza BV, Gallegos-Díaz de Leon JA, Munguía-Ramirez CD, and Hernández-Bello J. "Comparison of Three Different COVID-19 Vaccine Platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in Individuals with and Without Prior COVID-19: Reactogenicity and Neutralizing Antibodies." Immunology Letters 251-252 (2022): 20. https://doi.org/10.1016/j.imlet.2022.10.002.

MLA (9th ed.) Citation

JJ, Morales-Núñez, et al. "Comparison of Three Different COVID-19 Vaccine Platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in Individuals with and Without Prior COVID-19: Reactogenicity and Neutralizing Antibodies." Immunology Letters, vol. 251-252, 2022, p. 20, https://doi.org/10.1016/j.imlet.2022.10.002.